Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 61
Filter
3.
Rev Pneumol Clin ; 67(6): 363-6, 2011 Dec.
Article in French | MEDLINE | ID: mdl-22137281

ABSTRACT

Eosinophilic pleural effusions have multiple aetiologies. We report on the case of a 40-year-old man who experienced an eosinophilic pleural effusion with blood hypereosinophilia that occurred nine weeks after a treatment with valproic acid was introduced. Usual aetiologies of eosinophilic pleural effusion were excluded. Once valproic acid was discontinued, both pleural effusion and blood eosinophilia decreased rapidly. The persistence of a residual pleural effusion required the introduction of oral corticosteroids, which resulted in the effusion disappearing completely and rapidly. Valproic acid is a rare cause of eosinophilic pleural effusion. The effusion usually regresses when treatment is discontinued but short-term oral corticotherapy may be necessary in order to heal the patient.


Subject(s)
Eosinophilia/chemically induced , Pleural Effusion/chemically induced , Valproic Acid/adverse effects , Adult , Antimanic Agents/adverse effects , Blood Cell Count , Eosinophilia/complications , Eosinophilia/diagnostic imaging , Eosinophils/pathology , Humans , Male , Pleural Effusion/complications , Pleural Effusion/diagnostic imaging , Radiography, Thoracic
5.
Rev Pneumol Clin ; 59(3): 129-37, 2003 Jun.
Article in French | MEDLINE | ID: mdl-13130199

ABSTRACT

The use of inhaled glucocorticosteroids for the treatment of asthma raises the important question of short- and long safety. Thus the assessment of the benefit-risk ratio is an essential part of the development of powerful agents with reinforced topical activity. Several factors determine the optimal profile for an inhaled glucocorticoid: topical activity, systemic bioavailability (influence of the first-pass liver metabolism, inhalation device, patient- and disease-related factors), and pharmacokionetic behavior, liposolubility being one of the determining elements. Taken together these different factors produce a therapeutic index expressing the topical and systemic effects of inhaled glucocorticosteroids and their variability under the particular conditions of each patient. Al high-dose inhaled glucocorticoids have an impact on the adrenal gland which is easy to demonstrate but with rather insignificant clinical relevance. In children for example, there is a transient inhibition of bone growth with no impact on final height in adulthood. In adults; the effect on bone metabolism raises the risk of osteoporosis which must be prevented and detected in patients at risk. More data must be acquired concerning the ocular risk. Overall, significant adverse systemic effects are not observed with administration of inhaled glucocorticoids, but there remains a certain degree of uncertainty concerning the effects of long-term administration of low effective doses.


Subject(s)
Asthma/drug therapy , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Administration, Inhalation , Adrenal Glands/drug effects , Adult , Biological Availability , Bone Development/drug effects , Child , Dose-Response Relationship, Drug , Glucocorticoids/pharmacokinetics , Glucocorticoids/pharmacology , Humans , Osteoporosis/chemically induced
6.
Rev Mal Respir ; 17(3 Pt 2): 749-57, 2000 Aug.
Article in French | MEDLINE | ID: mdl-11076385

ABSTRACT

We have studied the characteristics of 202 cystic fibrosis adult patients, all with chronic respiratory symptoms, with a median age of 27 yrs (18 to 55 yrs) and a male predominance (56%). At genetic analysis, delta F508 homozygotes were 41%, delta F508 heterozygotes 42% and 17% had no delta F508. The respiratory disease was more severe and complications were more frequent in adults: hemoptysis in 14%, pneumothorax in 15%, lung transplantation in 25 patients. Chronic bronchial colonisation with Pseudomonas aeruginosa, in 76% of patients, contributed to making treatments more severe because of antibiotic i.v. courses and nebulised antibiotics. Respiratory function showed a mean FVC of 62 +/- 22% and a mean FEVI of 48 +/- 94%. External pancreatic insufficiency was found in 83%, diabetes in 14%. Intestinal occlusion syndromes were observed in 11% of patients and hepatic cirrhosis in 8%. In spite of the severity of the respiratory disease, theses patients succeeded in social and occupational insertion; 62% were independent, 18% had children and 77% were working or studying. Analysis of the patients according to age at diagnosis showed that, in 38 patients diagnosed after the age of 18 yrs, the respiratory disease was less severe, pancreatic insufficiency and non-respiratory complications were less frequent (34% had pancreatic insufficiency, 5% had diabetes and none had cirrhosis). This may partly be due to the presence of milder CFTR mutations. In conclusion, cystic fibrosis in adulthood frequently looks like an evolutive form of cystic fibrosis in childhood. Nevertheless, some late diagnosed forms in adults, with better prognosis, have been recently identified.


Subject(s)
Cystic Fibrosis , Adolescent , Adult , Age Factors , Cohort Studies , Cystic Fibrosis/complications , Cystic Fibrosis/diagnosis , Cystic Fibrosis/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Exocrine Pancreatic Insufficiency/diagnosis , Female , Heterozygote , Homozygote , Humans , Life Style , Male , Middle Aged , Mutation , Respiratory Function Tests , Respiratory Tract Infections/diagnosis , Socioeconomic Factors
7.
Medicine (Baltimore) ; 78(5): 321-37, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10499073

ABSTRACT

Pulmonary lymphangioleiomyomatosis (LAM) is a rare disorder of unknown cause characterized by peribronchial, perivascular, and perilymphatic proliferation of abnormal smooth muscle cells leading to cystic lesions. The hypothesis of hormonal dependence and the effectiveness of hormonal therapy have not yet been demonstrated conclusively, and the prevalence of extrathoracic manifestations and the survival of patients with LAM are somewhat contradictory. A multicentric retrospective study was conducted in an attempt to describe better the initial features, the diagnostic procedures, the associated lesions, and, above all, the management and course of LAM in a large homogeneous series of 69 stringently selected patients, with a majority of cases diagnosed since 1990. The aim of the study, based on a review of the literature, also was to provide a comprehensive view of this uncommon disease. The clinical features were in keeping with previous studies, but we found that exertional dyspnea and pneumothorax were the most common features, and chylous involvement was less frequent. LAM was diagnosed after menopause in about 10% of cases. The onset of LAM occurred during pregnancy in 20% of cases, and a clear exacerbation of LAM was observed in 14% of cases during pregnancy. Pulmonary LAM was diagnosed on lung histopathology in 83% of cases, but renal angiomyolipoma, observed in 32% of our patients, may be a useful diagnostic criterion when associated with typical multiple cysts on chest CT scan or with chylous effusion. Chest CT scan was more informative than chest X-ray (normal in 9% of cases), and may be indicated in spontaneous pneumothorax or renal angiomyolipoma in women of childbearing age. About 40% of the patients had a normal initial spirometry, while an obstructive ventilatory defect (44%), a restrictive ventilatory defect (23%), was observed in other patients. Initial diffusing capacity for carbon monoxide was frequently decreased (82%). Hormonal therapy was administered in 57 patients, but a clear > or = 15% improvement of FEV1 was observed in only 4 evaluable patients, treated with tamoxifen and progestogens (n = 2), progestogen (n = 1), and oophorectomy (n = 1). Probably 1 of the most urgent needs for clinical research in LAM is to test the currently available hormonal treatments in the context of international multicenter prospective controlled studies. Pleurodesis was performed in 40 patients. Lung transplantation was performed in 13 patients, 7.8 +/- 5.2 years after onset of LAM, in whom the mean FEV1 was 0.57 +/- 0.15 L. After a follow-up of 2.3 +/- 2.2 years, 9 patients were alive. Mean follow-up from onset of disease to either death or closing date was 8.2 +/- 6.3 years. Overall survival was better than usually reported in LAM, and Kaplan-Meier plot showed survival probabilities of 91% after 5 years, 79% after 10 years, and 71% after 15 years of disease duration.


Subject(s)
Lung Neoplasms/physiopathology , Lymphangioleiomyomatosis/physiopathology , Adolescent , Adult , Airway Obstruction/physiopathology , Angiomyolipoma/pathology , Antineoplastic Agents, Hormonal/therapeutic use , Chylothorax/physiopathology , Dyspnea/physiopathology , Female , Follow-Up Studies , Forced Expiratory Volume/physiology , Humans , Kidney Neoplasms/pathology , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology , Lung Neoplasms/therapy , Lymphangioleiomyomatosis/diagnosis , Lymphangioleiomyomatosis/pathology , Lymphangioleiomyomatosis/therapy , Menopause , Middle Aged , Muscle, Smooth/pathology , Neoplasms, Multiple Primary/pathology , Pneumothorax/physiopathology , Pregnancy , Pregnancy Complications, Neoplastic/diagnosis , Pulmonary Diffusing Capacity/physiology , Retrospective Studies , Spirometry , Tomography, X-Ray Computed
8.
J Allergy Clin Immunol ; 104(2 Pt 1): 402-10, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10452763

ABSTRACT

BACKGROUND: Angiotensin-converting enzyme (ACE) is a peptidase involved in the metabolism of several bioactive peptides. It may be involved in the airway inflammation and hyperresponsiveness that occur in asthma. OBJECTIVE: We studied the expression of ACE in the airway mucosa of normal and asthmatic subjects and assessed the relationship between ACE expression and airway inflammation and bronchial hyperresponsiveness in asthma. METHODS: We used immunohistochemistry to study the ACE expression and airway inflammation in bronchial biopsy samples obtained by fiberoptic bronchoscopy from 20 asthmatic subjects randomly assigned to groups treated with (n = 10) or without inhaled corticosteroids (n = 10) and from normal subjects (n = 10). Airway response to methacholine and bradykinin was also determined for all subjects. RESULTS: In normal subjects ACE was present in the surface epithelium, the endothelial cells of the lamina propria, and the submucosal glands, in which ACE was found in seromucous cells and in secreted mucus. ACE was not detected in smooth muscle cells and in most of the endothelial cells of the vascular network surrounding the glands. ACE was absent or present at lower levels in the surface epithelium of asthmatic subjects not treated with corticosteroids compared with those treated with corticosteroids and the control group. In asthmatic subjects low levels of ACE in the epithelium were associated with larger numbers of eosinophils in the epithelium and lamina propria. There was no relationship between ACE levels in the airway mucosa and airway responsiveness to methacholine and bradykinin. CONCLUSION: ACE expression is decreased in the epithelium of asthmatic patients and is associated with increased eosinophil inflammation.


Subject(s)
Asthma/enzymology , Eosinophils , Inflammation/enzymology , Peptidyl-Dipeptidase A/biosynthesis , Respiratory System/enzymology , Asthma/physiopathology , Biopsy , Bronchi/pathology , Bronchial Hyperreactivity/enzymology , Bronchoalveolar Lavage Fluid/cytology , Epithelium/enzymology , Forced Expiratory Volume , Humans , Immunohistochemistry
10.
Rev Pneumol Clin ; 55(5): 263-9, 1999 Oct.
Article in French | MEDLINE | ID: mdl-10637892

ABSTRACT

Lymphoangioleiomyomatosis (LAM) is a characteristic diffuse proliferation of abnormal smooth muscle fibers predominantly developing in the lung and leading to cystic destruction. An almost totally specific marker, HMB45, is available. This monoclonal antibody labels cells of the melanocyte line, LAM cells and renal angiomyolipoma cells. The antigen carried by all these cell lines is probably gp-100 involved in melanogenesis. Two gene loci are formally implicated in the pathogenesis of Bourneville tuberous sclerosis (BTS): TSC1 (9q 34.3) and TSC2 (16p 13.3). The TSC2 locus could be implicated in the pathogenesis of pulmonary LAM. LAM and BTS have similar clinical and histological features and could be two different phenotypic forms, distinguished strictly on a nosological basis, of the same disease. The hormone-dependence theory is suggested on the basis of purely clinical arguments, particularly the almost exclusive female predominance, generally during the period of genital activity. Certain counter arguments have also been put forward and consequently, since no in vitro cell culture model or animal model of LAM is available, it is not really possible to verify the hypothesis. Epidemiological data have been recently acquired in France with the constitution of the GERM"O"P registry of LAM cases in France. Recent technological progress in imaging techniques has also been helpful for earlier, more precise diagnosis. HMB45 immunolabeling improves diagnostic sensitivity on small tissue fragments obtained with transbronchial biopsies. The course of LAM appears to be different in certain patient subgroups. Certain patients develop rapidly fatal disease in months or years while in the majority of patients the disease is much less aggressive for years. A minority of patients also have very slowly evolving disease sometimes diagnosed after menopause. Lung transplantation remains the ultimate treatment in case of life-threatening prognosis.


Subject(s)
Lung Neoplasms , Lymphangioleiomyomatosis , Antigens, Neoplasm , Biomarkers, Tumor/blood , Biopsy , Female , France/epidemiology , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/epidemiology , Lung Neoplasms/etiology , Lung Neoplasms/therapy , Lung Transplantation , Lymphangioleiomyomatosis/diagnosis , Lymphangioleiomyomatosis/epidemiology , Lymphangioleiomyomatosis/etiology , Lymphangioleiomyomatosis/therapy , Melanoma-Specific Antigens , Neoplasm Proteins/blood , Prognosis , Registries , Repressor Proteins/genetics , Sensitivity and Specificity , Sex Distribution , Survival Analysis , Tuberous Sclerosis Complex 2 Protein , Tumor Suppressor Proteins
11.
Am J Ther ; 5(5): 307-11, 1998 Sep.
Article in English | MEDLINE | ID: mdl-10099074

ABSTRACT

Numerous studies have compared the duration of the cutaneous effect of cetirizine and loratadine. We assessed their nasal effects 24 hours after administration in patients with allergic rhinitis, using a randomized, double-blind, crossover, placebo-controlled trial. Nasal challenge was performed by nebulization of increasing doubling dosages of histamine (0.04-1.28 mg/nostril) in 12 patients (seven males, five females, aged 31 +/- 7 years). Nasal airway resistance was measured by posterior rhinomanometry 24 hours after intake of cetirizine (10 mg), loratadine (10 mg), or placebo. Baseline nasal airway resistance was identical on all study days (2.86 +/- 0.10 cm H2 O/L per second). Twenty-four hours after intake, the dose-response curve of nasal obstruction to histamine was significantly lower after treatment with cetirizine compared with placebo (P < 0.05). However, although the curve was lower on loratadine than on placebo, the curves did not differ significantly. In conclusion, our study shows significant efficacy of cetirizine, but not of loratadine, in the nose at 24 hours after a single dose. This suggests that the nasal action of cetirizine is longer lasting than that of loratadine in patients with allergic rhinitis.


Subject(s)
Cetirizine/pharmacology , Histamine H1 Antagonists/pharmacology , Loratadine/pharmacology , Nasal Mucosa/drug effects , Rhinitis, Allergic, Perennial/drug therapy , Rhinitis, Allergic, Seasonal/drug therapy , Adult , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Female , Histamine/pharmacology , Humans , Male
12.
Thorax ; 53(10): 879-81, 1998 Oct.
Article in English | MEDLINE | ID: mdl-10193377

ABSTRACT

BACKGROUND: An easy and reliable method to measure potential difference (PD) in the lower airways would be of interest in the field of cystic fibrosis. We have developed silver/silver chloride (Ag/AgCl) electrodes to measure PD in the lower airways. METHODS: To validate this technique the nasal PD measured with Ag/AgCl electrodes and with conventional perfused electrodes was compared in 16 patients. The range of PD measured with Ag/AgCl electrodes in the lower airways during fibreoptic bronchoscopy was determined in 14 adult patients and in nine the reproducibility of this technique was examined. RESULTS: Nasal PD values measured with Ag/AgCl and perfused electrodes were highly correlated (r = 0.985, p < 0.0001) and the limits of agreement (mean +/- 2SD of the difference) between the two methods were -1.91 mV and 1.53 mV. In the lower airways a progressive and slight decrease in PD values with decreasing airway diameter was observed in most patients. The mean (2SD) of the differences between the two tracheal measurements was 0.21 (1.73) mV. CONCLUSIONS: The use of Ag/AgCl electrodes gives a reliable and reproducible measurement of PD in the lower airways in humans.


Subject(s)
Bronchi/physiopathology , Cystic Fibrosis/physiopathology , Biosensing Techniques , Female , Humans , Male , Middle Aged , Molecular Probe Techniques
13.
Eur Respir J ; 10(3): 633-8, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9072997

ABSTRACT

Heat shock proteins (HSPs), which are important targets for gammadelta T-lymphocytes, are thought to play a role in inflammatory and immune diseases. The purpose of this study was to characterize, in asthma, the presence and distribution of alphabeta and gammadelta T-lymphocytes and of hsp60, hsp70 and hsp90 in bronchial biopsies, and to seek for a co-localization of gammadelta T-cells and HSPs. Ten subjects with mild atopic asthma and nine control subjects underwent fibreoptic bronchoscopy and bronchial biopsies, to which specific monoclonal antibodies and immunohistochemical techniques were applied. T-lymphocytes present in bronchi both of asthmatic and control subjects were predominantly of the alphabeta T-cell receptor phenotype (median 642 cells x mm(-2) (range 85-1,510 cells x mm(-2)), and 855 cells x mm(-2) (286-2,424 cells x mm(-2)), respectively), whereas, gammadelta T-lymphocytes were always rare (median 26 cells x mm(-2) (range 0-114 cells x mm(-2)), and 0 cells x mm(-2 (0-57 cells x mm(-2), respectively). Both in asthmatic and control subjects, bronchial epithelium was positive for hsp60, hsp70 and hsp90. There was no significant difference in the percentages of positive epithelial cells between asthmatic and control subjects. No co-localization of HSPs and gammadelta T-cells was observed. Our findings do not support the hypothesis that heat shock proteins and gammadelta T-cells play an important role in inflammatory and immune responses in mild asthma.


Subject(s)
Asthma/immunology , Bronchi/metabolism , Heat-Shock Proteins/biosynthesis , Receptors, Antigen, T-Cell, gamma-delta/immunology , T-Lymphocytes/immunology , Adult , Asthma/metabolism , Asthma/pathology , Biopsy , Bronchi/pathology , Bronchoscopy , Case-Control Studies , Female , Humans , Immunoenzyme Techniques , Male , Receptors, Antigen, T-Cell, alpha-beta/immunology , T-Lymphocytes/metabolism
14.
Allergy ; 52(2): 205-9, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9105526

ABSTRACT

Several studies have compared the cutaneous efficacy of cetirizine and loratadine and their onset of action. We assessed the nasal effect of these two antihistamines in a randomized, double-blind, crossover, placebo-controlled trial in order to compare objectively their efficacy and onset of action in the noses of patients with allergic rhinitis. Nasal challenge was performed by nebulization of increasing doubling doses of histamine (0, 0.04-1.28 mg/nostril) in 12 patients (eight men, four women, aged 22-39 years). Nasal airway resistance (NAR) was measured by posterior rhinomanometry either 1.5 h or 4 h after intake of cetirizine (10 mg), loratadine (10 mg), or placebo. Baseline NAR was identical between all study days (2.60-2.88 cmH2O.l-1.s). One and a half hours after intake, the increase in NAR induced by histamine was significantly reduced by both cetirizine and loratadine in contrast to placebo. However, with cetirizine the nasal obstruction was significantly lower than with loratadine (P < 0.05). Four hours after intake, a similar inhibition of the nasal obstruction caused by histamine was observed with both cetirizine and loratadine (P < 0.05). In conclusion, this study found cetirizine and loratadine to have similar nasal efficacy at therapeutic dosage 4 h after intake, whereas cetirizine was more effective than loratadine 1.5 h after intake. In agreement with the results observed in the skin, our study suggests a more rapid onset of action of cetirizine in the nose in allergic rhinitis.


Subject(s)
Cetirizine/pharmacology , Histamine H1 Antagonists/pharmacology , Loratadine/pharmacology , Nasal Mucosa/drug effects , Rhinitis, Allergic, Seasonal/drug therapy , Adult , Airway Resistance/drug effects , Animals , Cetirizine/administration & dosage , Cross-Over Studies , Double-Blind Method , Female , Histamine/pharmacology , Humans , Infant, Newborn , Loratadine/administration & dosage , Male , Nasal Provocation Tests , Time Factors
15.
Eur Respir J ; 9(11): 2207-14, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8947061

ABSTRACT

In cystic fibrosis (CF), relationships between genotype and phenotype have been shown for pancreatic status but not for pulmonary disease. One hundred and ten adult CF patients were classified according to the expected effect of their mutations on cystic fibrosis transmembrane conductance regulator (CFTR) protein: Group 1 (n=48) included deltaF508 homozygotes; Group 2 (n=26), patients with two "severe" mutations and no expected CFTR production; Group 3 (n=17), patients with expected partly functional CFTR corresponding to at least one "mild" mutation; Group 4 (n=19), patients with no mutation identified or only one identified "severe" mutation. As compared to Groups 1 and 2: patients from Groups 3 and 4 had higher arterial oxygen tension (Pa,O2) (9.5+/-1.9 and 9.9+/-1.5 vs 8.8+/-1.5 and 8.3+/-1.7 kPa, respectively p<0.02); and a slower decline in their pulmonary function, estimated by the mean annual loss in forced vital capacity (FVC) (1.2+/-1.0 and 1.5+/-1.1 vs 2.0+/-0.9 and 2.2+/-1.0%, respectively; p<0.01) and in forced expiratory volume in one second (FEV1) (1.7+/-1.1 and 1.9+/-1.3 vs 2.6+/-1.0 and 2.8+/-1.0%, respectively; p<0.005). They had fewer episodes of colonization of the airways by Pseudomonas aeruginosa, and colonization occurred at a more advanced age (median age 25 and 19 vs 15 and 17 yrs, respectively; p<0.01) and required fewer intravenous antibiotic courses (p<0.01). Pancreatic insufficiency was less frequent in Groups 3 (23%) and 4 (63%) than in Groups 1 (100%) and 2 (96%). This study suggests that the phenotype of adult cystic fibrosis patients, including the severity of the lung disease, is related to the severity of the cystic fibrosis transmembrane conductance regulator mutations.


Subject(s)
Cystic Fibrosis/genetics , Adolescent , Adult , Arteries , Cystic Fibrosis/physiopathology , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , DNA/analysis , Exocrine Pancreatic Insufficiency/genetics , Female , Forced Expiratory Volume , Genotype , Homozygote , Humans , Male , Mutation , Oxygen/blood , Phenotype , Pseudomonas aeruginosa/isolation & purification , Respiratory System/microbiology , Vital Capacity
16.
Am J Respir Crit Care Med ; 153(1): 381-90, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8542147

ABSTRACT

We investigated the relationship between airway inflammation and airway responsiveness, as assessed by PD15, to methacholine and to bradykinin in asthmatic patients. Bronchoalveolar lavage (BAL), bronchial biopsies, and methacholine and bradykinin challenges were performed in 18 nonsmoking subjects with mild or moderate perennial asthma. Bradykinin PD15 correlated negatively with eosinophil count in BAL (p < 0.05), in the epithelium (p < 0.05), in the lamina propria (p = 0.02) and in the total submucosa (p < 0.01). Conversely, no significant correlation existed between airway responsiveness to methacholine and eosinophil count in BAL or in airway mucosa. Airway responsiveness to either agonist did not correlate with the thickness of the basement membrane, the shedding of the airway epithelium, the count of lymphocytes in the airway mucosa, or the percentage of neutrophils, lymphocytes, and macrophage in BAL. The presence of degranulated eosinophils was associated with an increased number of eosinophils in the airway epithelium (p = 0.04), in the lamina propria (p = 0.03), in the total submucosa (p = 0.02), and with increased airway responsiveness to bradykinin (p < 0.02). We conclude that in asthmatic patients, airway responsiveness to bradykinin but not to methacholine is related to the magnitude of eosinophilic inflammation in the airway mucosa.


Subject(s)
Asthma/pathology , Bradykinin , Bronchi/pathology , Bronchial Provocation Tests , Bronchoalveolar Lavage Fluid/cytology , Eosinophils , Adult , Aged , Biopsy , Bronchoscopy , Data Interpretation, Statistical , Female , Humans , Lymphocytes , Macrophages , Male , Methacholine Chloride , Middle Aged , Neutrophils
17.
Rev Pneumol Clin ; 52(2): 137-43, 1996.
Article in French | MEDLINE | ID: mdl-8761644

ABSTRACT

Several studies have been devoted to the possible deleterious effects of inhaled corticosteroids. These products are effective and have been widely used for longer and longer periods. Tests used to detect systemic effects are now quite sensitive allowing us to identify infraclinical purely biological effects resulting from minimal doses. The real value of these tests in predicting long-term deleterious effects such as adrenal failure, osteoporosis or growth retardation are now recognized. However, it is difficult to incriminate corticosteroids alone in certain cases because "parasite" conditions are often created by systemic corticosteroid therapy and because asthma alone can lead to deleterious extrapulmonary effects which should not be considered to result from treatment alone, emphasizing the need for carefully controlled studies. Despite the description of multiple systemic effects, the clinical consequences of long-term inhaled corticosteroids are not at all in the same range as oral corticosteroids. Nevertheless, there is some debate as to the strict indications for inhaled corticosteroids in adults and in children. The use of minimal effective doses in asthma is a primum non nocere.


Subject(s)
Anti-Asthmatic Agents/adverse effects , Anti-Inflammatory Agents/adverse effects , Asthma/drug therapy , Administration, Inhalation , Administration, Topical , Adolescent , Adult , Child , Ethics, Medical , Glucocorticoids , Humans
18.
Allergy ; 50(12): 970-5, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8834826

ABSTRACT

We have investigated the nasal response to substance P after pollen exposure in seasonal allergic rhinitic patients. Seven patients with strictly seasonal allergic rhinitis were studied during the pollen season, 24 h after nasal challenge with pollen. They received increasing doses of nebulized substance P (0 to 80 nmol) in each nostril. Responses were assessed by measurement of nasal airway resistance by posterior rhinomanometry and quantification of albumin, histamine, and inflammatory cells in the nasal lavage fluid. Nasal airway resistance increased in a dose-dependent manner after substance P challenge. Protein and albumin in nasal lavage fluids increased after administration of substance P: from 2.6 +/- 0.3 to 6.8 +/- 1.1 mg for protein (P < 0.01) and from 0.2 +/- 0.1 to 3.1 +/- 0.6 mg for albumin (P < 0.02). Expressed as a percentage of total protein, albumin increased from 10.5 +/- 3.6% to 39.9 +/- 3.5% (P < 0.02), suggesting occurrence of plasma leakage. No histamine release was observed after challenge with substance P. Total cell counts significantly increased from 11.4 +/- 2.4 to 41.8 +/- 17.3 x 10(3) cells/ml after substance P (P < 0.05). Eosinophils were already numerous before substance P challenge (2.1 +/- 0.7 x 10(3) cells/ml), and the number of eosinophils markedly increased in all patients after substance P (for the whole group, 25.8 +/- 13.3 cells/ml, P < 0.05). In contrast, the number of neutrophils only slightly increased in five patients, and changes did not reach significance for the group as a whole. Our results show that substance P induces nasal obstruction and albumin extrusion in allergic rhinitic patients after repeated pollen exposure. These vascular phenomena are associated with recruitment of eosinophils. Since substance P is known to be released after nasal allergen challenge, our data suggest a role for substance P in the chronic eosinophilic inflammation of the nasal mucosa observed in symptomatic allergic rhinitis.


Subject(s)
Eosinophils/drug effects , Nasal Cavity/drug effects , Nasal Lavage Fluid/cytology , Rhinitis, Allergic, Seasonal/etiology , Substance P/pharmacology , Administration, Intranasal , Adult , Airway Resistance/drug effects , Dose-Response Relationship, Drug , Female , France , Humans , Male , Nasal Lavage Fluid/chemistry , Pollen/immunology
19.
J Clin Invest ; 96(1): 12-21, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7615781

ABSTRACT

We studied the perception of bronchoconstriction in asthmatic subjects who were randomly treated with inhaled beta 2 agonist given either alone (n = 9) or associated with inhaled corticosteroids (n = 9). Methacholine and bradykinin challenges, bronchoalveolar lavage, and bronchial biopsies were performed in all subjects. After each dose of agonist, breathlessness was assessed using a visual analog scale (VAS) and the forced expiratory volume in 1 s (FEV1) was measured. The relationship between VAS scores and FEV1 and the slope of the regression line of VAS scores on the corresponding FEV1 (VAS/FEV1 slope) were analyzed for each agonist. Subjects without corticosteroids had good perception of methacholine but poor perception of bradykinin-induced bronchoconstriction. In subjects with corticosteroids, bronchoconstriction was well perceived whatever the agonist. VAS/FEV1 slopes for bradykinin but not for methacholine correlated negatively with the magnitude of eosinophilic inflammation in airway mucosa. VAS/FEV1 slopes for each agonist correlated positively with the percentage of basement membrane covered by airway epithelium. We conclude that in asthmatic patients perception of bronchoconstriction is related to eosinophilic inflammation and to epithelial damage in airways and that corticosteroid treatment is associated with improved perception of bronchoconstriction induced by bradykinin, a mediator endogenously produced in asthma.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Asthma/physiopathology , Bronchi/pathology , Bronchoconstriction/drug effects , Eosinophils/pathology , Inflammation/physiopathology , Adult , Aged , Asthma/drug therapy , Bradykinin/pharmacology , Epithelium/pathology , Female , Humans , Inflammation/pathology , Male , Methacholine Chloride/pharmacology , Middle Aged , Perception
20.
Rev Pneumol Clin ; 51(4): 233-7, 1995.
Article in French | MEDLINE | ID: mdl-7501941

ABSTRACT

Lymphangiomyomatosis is a rare disease which affects young women of childbearing age. Ten women with pulmonary lymphangiomyomatosis were treated with antiestrogen therapy from 3 to 9 years (mean time of treatment: 5.3 years). Efficacy of treatment was evaluated by clinical, radiological, pulmonary function testing response as well as the overall long-term outcome. Four patients died of respiratory failure after 3, 5, 5 and 9 years of treatment. Of the 6 patients remaining alive, respiratory function deteriorated in 4 cases after a transient period of mild improvement lasting 3 years in 2 cases. Two patients appeared stable after 3 and 7 years of treatment. Without a control group, although a longer time of survival along these last years, it seems difficult to impute this benefit to the sole antiestrogen treatment and the overall long term prognosis of the disease remains really uncertain.


Subject(s)
Estrogen Antagonists/therapeutic use , Lung Diseases/drug therapy , Lymphangioleiomyomatosis/drug therapy , Adult , Estrogen Antagonists/adverse effects , Female , Follow-Up Studies , Humans , Lung Diseases/physiopathology , Lung Diseases/surgery , Lymphangioleiomyomatosis/physiopathology , Lymphangioleiomyomatosis/surgery , Middle Aged , Ovariectomy , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...